SULT1A1 and breast cancer: In our study, CNV deletions overlapping SULT1A1 were identified in 1.7% of BRCA1 pathogenic variant carriers and they suggested a decreased breast cancer HR (HR = 0.73, 95%CI = 0.59–0.91, p = 9.1 × 10−3).